Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

In recent years, scientists have discovered that some chemotherapy drugs not only kill cancer cells directly, but at least in some patients, mysteriously also trigger their immune system to attack the ...

For five decades, scientists have known about a notorious cancer-causing enzyme called SRC. But they always assumed it only ...

Baylor University researchers have published a novel approach to fight colorectal cancer, using modified food-borne bacteria as a courier to deliver potent cancer-killing proteins into tumor cells.

Baylor University researchers have published a novel approach to fight colorectal cancer, using modified bacteria as a courier to deliver potent cancer-killing proteins into tumor cells. Michael S.

Amy Dowden has opened up about her desire to have children after being forced into medically-induced menopause following her ...

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout ...

The soap star, 68, revealed she is battling the disease earlier this year after being diagnosed just after she'd relocated to ...

Meet 5 hot biotechs in Arizona, from Phoenix to Tucson, that have raised significant funding over the past decade.

Australians have spoken of using a dangerous and corrosive substance to treat their skin cancer — but doctors warn patients have been misled and risk serious disfigurement or delayed diagnosis.

Immune system cells can be engineered outside of the body in a type of therapy called CAR-T. Now, Johns Hopkins scientists are developing ways to sidestep such cell manufacturing with a biodegradable ...

NEW YORK – Cbio will begin a European Phase I/II trial of its autologous T-cell therapy novoleucel for patients with late-stage cervical cancer, with initial results expected by the end of the year.